The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment
The DOI matches its Crossref record, with a small difference in title or year; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The chylomicronemia syndrome occurs when triglyceride levels are severely elevated (usually >16.95 mmol/L [1500 mg/dL]) and is characterized by such clinical features as abdominal pain, acute pancreatitis, eruptive xanthomas, and lipemia retinalis. It may result from 1 of 3 conditions: the presence of secondary forms of hypertriglyceridemia concurrent with genetic causes of hypertriglyceridemia, termed multifactorial chylomicronemia syndrome (MFCS); a deficiency in the enzyme lipoprotein lipase and some associated proteins, termed familial chylomicronemia syndrome (FCS); or familial partial lipodystrophy. Most chylomicronemia syndrome cases are the result of MFCS; FCS is very rare. In all these conditions, triglyceride-rich lipoproteins accumulate because of impaired plasma clearance. This review describes the 3 major causes of the chylomicronemia syndrome; their consequences; and the approaches to treatment, which differ considerably by group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multifactorial chylomicronemia syndrome is the most common of the 3 conditions that elevate triglycerides levels high enough to provoke the characteristic clinical features of excess chylomicronemia, which include lipemia retinalis, eruptive xanthomas, abdominal pain, and hyperlipidemic pancreatitis (42).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [42]
In the citing paper
“Clearance of triglycerides from plasma is saturable when plasma triglyceride levels exceed approximately 500 to 700 mg/dL and further input of chylomicrons and VLDL into plasma cannot readily be removed, leading to marked hypertriglyceridemia and chylomicronemia, even after an overnight fast (42).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [42]
In the citing paper
“Lipoprotein lipase-mediated lipolysis of newly secreted TRLs is a saturable process, and as secretion rates and plasma TG levels rise, lipolysis falls.14”
From Clinical review on triglycerides (2020) · cites this paper as [14]
In the citing paper
“However, pancreatitis risk is highest in rare patients with monogenic chylomicronaemia, in which chylomicrons are indeed the predominant species, with low to undetectable levels of remnants and downstream lipoproteins due to severely impaired lipolytic machinery.6,14,29,30”
From Clinical review on triglycerides (2020) · cites this paper as [14]
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Fat Transport in Lipoproteins — An Integrated Approach to Mechanisms and Disorders
Fredrickson, D. S., Levy, R. I., & Lees, R. S. (1967) · New England Journal of Medicine · doi:10.1056/nejm196701052760107 · Cited by 1,910
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Prognostic signs and the role of operative management in acute pancreatitis.
Ranson, J. H. C., Rifkind, K., Roses, D. F., Fink, S. D., Eng, K., & Spencer, F. C. (1974) · PubMed · Cited by 1,347
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635
EPIC-InterAct Consortium, Lotta, L. A., Cambridge FPLD1 Consortium, Gulati, P., Day, F. R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K. J., Eicher, J. D., et al. (2017) · Nature Genetics · doi:10.1038/ng.3714 · Cited by 585
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573
Research works printed but not linked: 3
- Fortson MR, 1995, Am J Gastroenterol, 90, 2134
- Ranson JH, 1974, Surg Gynecol Obstet, 139, 69
- Khan AS, 2010, JOP, 11, 545
Cited by
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“6,14,29,30 While TG >10mmol/L (885mg/dL) may be sufficient to precipitate acute pancreatitis without additional factors, in many patients, especially those experiencing pancreatitis at relatively low TG levels, additional factors such as alcohol consumption, gallstone disease or certain medications…”
BackgroundVirani, S. S., Morris, P. B., Agarwala, A., Ballantyne, C. M., Birtcher, K. K., Kris-Etherton, P. M., Ladden-Stirling, A. B., Miller, M., Orringer, C. E., & Stone, N. J. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.011 · Cited by 341
Genetics of hypertriglyceridemia
Dron, J. S., & Hegele, R. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00455 · Cited by 244
Management of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 223
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
Watts, G. F., Rosenson, R. S., Hegele, R. A., Goldberg, I. J., Gallo, A., Mertens, A., Baass, A., Zhou, R., Muhsin, M., Hellawell, J., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409368 · Cited by 215
Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association
Brown, E. E., Sturm, A. C., Cuchel, M., Braun, L. T., Duell, P. B., Underberg, J. A., Jacobson, T. A., & Hegele, R. A. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.04.011 · Cited by 148
“Another common dyslipidemia is hypertriglyceridemia, which if severe can lead to life-threatening acute pancreatitis.(21) Clinical features of the most severe forms include eruptive xanthomas, lipemia retinalis, hepatosplenomegaly, and increased risk of acute pancreatitis.”
BackgroundKirkpatrick, C. F., Sikand, G., Petersen, K. S., Anderson, C. A. M., Aspry, K. E., Bolick, J. P., Kris-Etherton, P. M., & Maki, K. C. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.05.099 · Cited by 118
A Comprehensive Update on the Chylomicronemia Syndrome
Goldberg, R. B., & Chait, A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.593931 · Cited by 117
“This provides support for the notion that the pathophysiological disturbances in triglyceride metabolism that accompany diabetes can interact with polygenic forms of HTG to result in triglyceride levels that exceed the saturation point for triglyceride removal from plasma (47), thereby leading to severe HTG and the MF…”
BackgroundInfluentialSelf-citationSoffer, D. E., Marston, N. A., Maki, K. C., Jacobson, T. A., Bittner, V. A., Peña, J. M., Thanassoulis, G., Martin, S. S., Kirkpatrick, C. F., Virani, S. S., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.08.013 · Cited by 115
Lipophagy and Lipolysis Status in Lipid Storage and Lipid Metabolism Diseases
Kłoska, A., Węsierska, M., Malinowska, M., Gabig‐Cimińska, M., & Jakóbkiewicz‐Banecka, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176113 · Cited by 127
Esan, O., & Wierzbicki, A. S. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s224771 · Cited by 80
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
Gaudet, D., Clifton, P., Sullivan, D., Baker, J., Schwabe, C., Thackwray, S., Scott, R., Hamilton, J., Given, B., Melquist, S., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200325 · Cited by 71
Lipid-lowering in diabetes: An update
Chait, A., Eckel, R. H., Vrablík, M., & Zambon, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117313 · Cited by 81
Self-citationFamilial chylomicronemia syndrome: An expert clinical review from the National Lipid Association
Javed, F., Hegele, R. A., Garg, A., Patni, N., Gaudet, D., Williams, L., Khan, M., Li, Q., & Ahmad, Z. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.03.013 · Cited by 60
The polygenic nature of mild-to-moderate hypertriglyceridemia
Dron, J. S., Wang, J., McIntyre, A. D., Cao, H., & Hegele, R. A. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.003 · Cited by 58
Chylomicronemia from GPIHBP1 autoantibodies
Miyashita, K., Lutz, J., Hudgins, L. C., Toib, D., Ashraf, A. P., Song, W., Murakami, M., Nakajima, K., Ploug, M., Fong, L. G., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.r120001116 · Cited by 54
Chait, A. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.010 · Cited by 58
Self-citationPatel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01525-5 · Cited by 57
“hypertriglyceridemia pointing to potentially different aetiologies with genetic factors contributing to risk earlier in life [22].”
Background10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes
Belhassen, M., Van Ganse, E., Nolin, M., Bérard, M., Bada, H., Bruckert, E., Krempf, M., Rebours, V., Valero, R., & Moulin, P. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa838 · Cited by 47
Witztum, J. L., Gaudet, D., Arca, M., Jones, A., Soran, H., Gouni-Berthold, I., Stroes, E. S. G., Alexander, V. J., Jones, R., Watts, L., et al. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2023.03.007 · Cited by 44
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment
Gallo, A., Béliard, S., D’Erasmo, L., & Bruckert, É. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00885-1 · Cited by 47
Spagnuolo, C. M., Wang, J., McIntyre, A. D., Kennedy, B. A., & Hegele, R. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae613 · Cited by 42
Deshotels, M. R., Hadley, T. D., Roth, M. M., Agha, A. M., Pulipati, V. P., Nugent, A. K., Virani, S. S., Nambi, V., Moriarty, P. M., Davidson, M. H., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318445 · Cited by 41
Dhindsa, S., Sharma, A., Al-Khazaali, A., Sitaula, S., Nadella, S., McKee, A. M., Albert, S. G., Bourey, R. E., & Dandona, P. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz019 · Cited by 37
“89 Length of stay, days 7 [5, 17] 5 [4, 7] 0.”
D. Bruce, K., Tang, M., Reigan, P., & H. Eckel, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218338 · Cited by 36
“Abbreviations LPL Lipoprotein Lipase Aβ Amyloid-Beta AD Alzheimer’s Disease ApoC-II ApoproteinC-II ApoC-III ApoproteinC-III ChEIs Cholinesterase inhibitors DMTs Disease-modifying therapeutics TG Triglycerides VLDL Very-low-density lipoprotein CVD Cardiovascular Disease CNS Central Nervous system OPCs Oligodendrocytes…”
BackgroundSafety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
“The metabolic blockade is so severe that smaller lipoproteins normally formed by remodeling of chylomicrons are deficient [3].”
BackgroundInfluentialChylomicronemia syndrome: Familial or not?
Warden, B. A., Minnier, J., Duell, P. B., Fazio, S., & Shapiro, M. D. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.01.014 · Cited by 34
Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia
Kolovou, G., Kolovou, V., & Katsiki, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040982 · Cited by 33
“Fasting TG levels are usually >1000 mg/dL (11 mmol/L) and can even reach >10,000 mg/dL (110 mmol/L) [6].”
BackgroundParagh, G., Németh, Á., Harangi, M., Banach, M., & Fülöp, P. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01631-z · Cited by 38
“The condition is characterized by limited capacity of adipose tissue to store fat leading to subsequent metabolic abnormalities, such as insulin resistance, liver steatosis and severe hypertriglyceridemia [2, 63, 64].”
BackgroundPediatric Dyslipidemia—Beyond Familial Hypercholesterolemia
Lazarte, J., & Hegele, R. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.03.020 · Cited by 32
The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants
Perera, S. D., Wang, J., McIntyre, A. D., Dron, J. S., & Hegele, R. A. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.11.007 · Cited by 31
Berberich, A. J., Ouédraogo, A. M., Shariff, S. Z., Hegele, R. A., & Clemens, K. K. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01517-6 · Cited by 31
“Previous studies conducted elsewhere have suggested that secondary causes of VS-HTG, include obesity and metabolic syndrome, poorly controlled diabetes, nephrotic syndrome, severe hypothyroidism, oral estrogen or tamoxifen, glucocorticoids, beta blockers, retinoids and HIV antiretroviral regimens [3, 12, 13].”
BackgroundAraz, F., Bakıner, O., Bağır, G. Ş., Soydaş, B., Özer, B., & Kozanoğlu, İ. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002025 · Cited by 30
A protein of capillary endothelial cells, GPIHBP1, is crucial for plasma triglyceride metabolism
Young, S. G., Song, W., Yang, Y., Birrane, G., Jiang, H., Beigneux, A. P., Ploug, M., & Fong, L. G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211136119 · Cited by 29
Volanesorsen for treatment of familial chylomicronemia syndrome
Lazarte, J., & Hegele, R. A. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1955348 · Cited by 26
“Although the TG elevation can be as severe as in FCS, MCM patients do not have a complete blockade in lipolysis, due to the very different underlying genetic architecture [2].”
BackgroundInfluentialIntermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies
Ashraf, A. P., Miyashita, K., Nakajima, K., Murakami, M., Hegele, R. A., Ploug, M., Fong, L. G., Young, S. G., & Beigneux, A. P. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.012 · Cited by 24
Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity
Brisson, D., Larouche, M., Chebli, J., Khoury, É., & Gaudet, D. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.02.002 · Cited by 21
Medical management of hypertriglyceridemia in pancreatitis
Gligorijevic, N., Stefanović-Račić, M., & Kershaw, E. E. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000956 · Cited by 25
Tremblay, K., Gaudet, D., Khoury, É., & Brisson, D. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa056 · Cited by 21
“MCM is a multifactorial disorder, most often polygenic, and frequently associated with overweight (or obesity) and other elements of the metabolic syndrome in addition to unhealthy life habits [5].”
BackgroundIs Genetic Testing in Hypertriglyceridemia Useful?
Hegele, R. A. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318621 · Cited by 20
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Brinton, E. A., Eckel, R. H., Gaudet, D., Ballantyne, C. M., Baker, B. F., Ginsberg, H. N., & Witztum, J. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119114 · Cited by 22
Self-citationNémeth, Á., Harangi, M., Daróczy, B., Juhász, L., Paragh, G., & Fülöp, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154311 · Cited by 19
“With a mortality rate of 2–5%, acute pancreatitis is the most dangerous consequence of hypertriglyceridemia [8].”
BackgroundGuay, S., Paquette, M., Taschereau, A., Girard, L., Desgagné, V., Bouchard, L., Bernard, S., & Baass, A. W. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117489 · Cited by 19
Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report
Lutz, J., Dunaj-Kazmierowska, M., Arcan, S., Kassner, U., Miyashita, K., Murakami, M., Ploug, M., Fong, L. G., Young, S. G., Nakajima, K., et al. (2020) · Annals of Internal Medicine · doi:10.7326/l20-0327 · Cited by 18
Patel, S. B., Belalcazar, L. M., Afreen, S., Balderas, R., Hegele, R. A., Karpe, F., Ponte-Negretti, C. I., & Rajpal, A. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.014 · Cited by 23
Saadatagah, S., Larouche, M., Naderian, M., Nambi, V., Brisson, D., Kullo, I. J., Duell, P. B., Michos, E. D., Shapiro, M. D., Watts, G. F., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.03.012 · Cited by 30
“15,24,26 These factors can contribute to hypertriglyceridemia by increasing production and/or decreasing clearance of TRL; of note, large VLDL and chylomicrons share a common catabolic pathway via LPL. 20,27 MCS can present at any age, though it typically manifests later than FCS, and is often…”
An overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
APOC3 Interference for Familial Chylomicronaemia Syndrome
Hegele, R. A. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.82 · Cited by 17
“In pre-genomic times, FCS was diagnosed biochemically by demonstrating the absence of lipolytic activity in plasma after heparin infusion, although the assay was cumbersome and somewhat variable.(1,2) Currently, genetic diagnosis is the gold standard for FCS.”
BackgroundMethodInfluentialSaadatagah, S., Larouche, M., Naderian, M., Nambi, V., Brisson, D., Kullo, I. J., Duell, P. B., Michos, E. D., Shapiro, M. D., Watts, G. F., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100978 · Cited by 22
“Table 1 outlines the key differences between FCS and MCS. FCS, a rare disease affecting approximately 1 to 10 individuals per 1,000,000 [15,16], is an autosomal recessive disease caused by the biallelic combination of pathogenic variants that impair the lipolytic action of LPL, either defects in…”
InfluentialFantino, M., Paquette, M., Blais, C., Saint-Pierre, N., Bourque, L., Baass, A. W., & Bernard, S. (2022) · Nutrition Research · doi:10.1016/j.nutres.2022.02.001 · Cited by 17
Multifactorial chylomicronemia syndrome
Chait, A. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000846 · Cited by 18
“Triglyceride-induced pancreatitis has a worse prognosis than other forms of pancreatitis, with an approximate doubling of renal and respiratory failure, a nearly four-fold increase Several other features of the chylomicronemia eruptive xanthomata, lipemia retinalis, memory loss…”
BackgroundSelf-citationCan genetic testing help in the management of dyslipidaemias?
Lazarte, J., & Hegele, R. A. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000690 · Cited by 15
Zheng, C., Zheng, Y., & Zheng, Z. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01562-z · Cited by 12
“Besides, some authors argue that fasting often leads to a significant reduction in TG concentrations [27].”
BackgroundMasson, W., Lobo, M., Nogueira, J. P., Corral, P., Barbagelata, L., & Siniawski, D. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09893-x · Cited by 12
Tsimikas, S., Ginsberg, H. N., Alexander, V. J., Karwatowska‐Prokopczuk, E., Dibble, A., Li, L., Witztum, J. L., & Hegele, R. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.018 · Cited by 12
Fitts, E. C., Lee, P., & Yates, S. G. (2019) · Transfusion · doi:10.1111/trf.15532 · Cited by 12
“F amilial chylomicronemia syndrome (FCS) is a group of rare genetic disorders with an estimated prevalence of one in one million people.(1) FCS is a disorder often associated with multiple medical complications, with pancreatitis being among the most severe.”
BackgroundSun, C., McCudden, C. R., Brisson, D., Shaw, J. L. V., Gaudet, D., & Ooi, T. C. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz010 · Cited by 15
Ganda, O. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000694 · Cited by 12
Approach to the Patient With Moderate Hypertriglyceridemia
Subramanian, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac085 · Cited by 13
Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2025
Rached, F. H., Miname, M. H., Rocha, V. Z., Zimerman, A., Cesena, F. Y., Sposito, A. C., Santos, R. D., Behr, P. E. B., Bianco, H. T., Alves, R. J., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250640 · Cited by 96
Prevention and treatment of hypertriglyceridemia-mediated acute pancreatitis: A narrative review
Subramanian, S., Soran, H., Kessler, A. S., McClain, M. R., Eckel, R. H., & Rosenson, R. S. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106648 · Cited by 13
Self-citationHipertrigliceridemia familiar/hipertrigliceridemia poligénica
Lahoz, C., & Mostaza, J. M. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.12.014 · Cited by 11
Cheng, Y., Li, T., Tan, P., Du, Y., Huang, Z., Shi, H., Cai, T., Chen, Y., & Fu, W. (2022) · Endocrine · doi:10.1007/s12020-022-03025-8 · Cited by 11
Approach to the Adult Patient with Chylomicronemia
Hegele, R. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf701 · Cited by 14
Peterson, A. L. H., Ashraf, A. P., Bachman, J., Hegele, R. A., Rashad, M., South, A. M., Tran, A. H., Zachariah, J. P. V., & Wong, J. P. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000195 · Cited by 8
Metzner, T., Leitner, D. R., Mellitzer, K., Beck, A., Sourij, H., Stojaković, T., Reishofer, G., März, W., Landmesser, U., Scharnagl, H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10010193 · Cited by 10
“Angiopoietin-like proteins 3 and 4 (ANGPTL-3/4) inhibit lipoprotein lipase by forming complexes with angiopoietinlike protein 8 (ANGPTL-8), while glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein-1 (GPIHBP-1) facilitates the transfer of lipoprotein lipase to the luminal side of the endothe…”
BackgroundApproach to patients with hypertriglyceridemia
Chait, A., & Feingold, K. R. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101659 · Cited by 11
Self-citationQuilomicronemia familiar y quilomicronemia multifactorial
Muñiz-Grijalvo, O., & Díaz-Díaz, J. L. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.011 · Cited by 9
Novel PPARG mutation in multiple family members with chylomicronemia
Glodowski, M., Christen, S., Saxon, D. R., Hegele, R. A., & Eckel, R. H. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.03.006 · Cited by 8
Self-citationWhat is the phenotype of heterozygous lipoprotein lipase deficiency?
Hegele, R. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000974 · Cited by 9
“…with heterozygous LPL deficiency, the phenotype can vary from normal to severe in the same patient In an adult with severe hypertriglyceridemia, it is more likely that a DNA sequencing report will reveal heterozygosity Specifically, 15 – 25 vs. 1 – 6% of adults with severe…”
InfluentialGenetic and functional studies of the LMF1 gene in Thai patients with severe hypertriglyceridemia
Plengpanich, W., Muanpetch, S., Charoen, S., Kiateprungvej, A., & Khovidhunkit, W. (2020) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2020.100576 · Cited by 8
“Although post-heparin LPL activity is considered highly variable among assays and laboratories [6], it might be useful in documenting the in vivo functionality of the new variants identified.”
BackgroundTremblay, K., Brisson, D., & Gaudet, D. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0123 · Cited by 8
Nozue, T., Tada, H., Murakami, M., & Michishita, I. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.10.005 · Cited by 6
Apolipoprotein C-II: a new look at an old protein
Hegele, R. A. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad237 · Cited by 5
Ain, Q. U., Cevc, M., Marusic, T., Šikonja, J., Sadiq, F., Šuštar, U., Mlinarič, M., Kovač, J., Batool, H., Khan, M. I., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1387419 · Cited by 6
“LPL de fi ciency (OMIM #238600) is characterised by the accumulation of TG-rich lipoproteins (11).”
BackgroundBardey, F., Rieck, L., Spira, D., März, W., Binner, P., Schwab, S. K., Kleber, M. E., Danyel, M., Barkowski, R., Bobbert, T., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100589 · Cited by 5
“Among the most common nongenetic factors that lead to HTG are obesity, diabetes mellitus (43), alcohol consumption (6, 44), and metabolic syndrome (6).”
Chylomicronemia through a burr hole: A case report
Loh, W. J., Bakthavachalam, R., Subramaniam, T., Pek, S. L. T., Chua, F., Lee, L., & Watts, G. F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1020397 · Cited by 5
A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment
Mangeshkar, S., Nazarenko, N., Varrias, D., Spanos, M., Borkowski, P., Alhuarrat, M. A. D., Li, W., Kishore, P., & FAILLACE, R. T. (2023) · Cureus · doi:10.7759/cureus.41424 · Cited by 4
“In general terms, treatment should involve dietary fat restriction for all patients tolerating oral intake, until triglyceride levels are lowered below 1000 mg/dL [6].”
BackgroundInfluentialLi, Y., Hu, M., Han, L., Feng, L., Yang, L., Chen, X., Du, T., Yao, H., & Chen, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.831133 · Cited by 4
Ballantyne, C. M., Baass, A. W., Rosenson, R. S., Hegele, R. A., Nicholls, S. J., Vasas, S., Clifton, P. M., Lucas, K. J., Páll, D., Zhou, R., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101523 · Cited by 3
“…from severe dietary fat restriction, which is supported mainly by observational and case-series data, there are currently no effective therapeutic options proven to reduce the risk of AP in patients with hypertriglyceridemia outside of patients with Familial Chylomicronemia Syndrome (FCS) [8 – 12].”
Basheer, H., Nakhaee, B., & Jialal, I. (2021) · Laboratory Medicine · doi:10.1093/labmed/lmab127 · Cited by 3
Nuevos tratamientos en la hipertrigliceridemia y en la hiperquilomicronemia
García-Díaz, J. D. D. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2019.11.003 · Cited by 3
Tratamiento de la quilomicronemia
Hermoso, A. N., & Valdivielso, P. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.01.004 · Cited by 3
ANGPTL3 and ANGPTL8 in Thai subjects with hyperalphalipoproteinemia and severe hypertriglyceridemia
Kaewkrasaesin, C., Chatchomchuan, W., Muanpetch, S., & Khovidhunkit, W. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.08.059 · Cited by 3
Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis
Chen, H., Li, X., Chen, J., Zhao, Y., Zhang, W., Li, H., & Qi, X. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178148 · Cited by 2
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Carotid intima-medial thickness in patients with severe hypertriglyceridemia
Ahmad, M., Kennedy, B. A., Son, S., McIntyre, A. D., Lazarte, J., Wang, J., & Hegele, R. A. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.04.001 · Cited by 1
“In contrast, the association of severe HTG with risk of atherosclerotic cardiovascular disease (ASCVD) is less clear [8].”
BackgroundRussian extreme hypertriglyceridemia registy (REGGI): a call to action
Чубыкина, У. В., Владиславович, Е. М., Sokolov, A. A., Vasiluev, P. A., Ivanova, O. N., & Zakharova, E. Y. (2024) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2024-3098 · Cited by 1
Quilomicronemia multifactorial: claves para la detección de las formas severas
Muñiz-Grijalvo, O., Echevarría, A. B., Corbo, M. J. A., & Díaz-Díaz, J. L. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.11.003 · Cited by 1
Heterozygous pathogenic PPARG variants in patients with severe hypertriglyceridemia
Hang, S., Wang, J., Taboun, Z., McIntyre, A. D., & Hegele, R. A. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.021 · Cited by 2
Bubnova, M. G., Ezhov, M. V., Aronov, D. M., Galyаvich, A. S., Gurevich, V. S., Duplyakov, D. V., Zafiraki, V. K., Karamnova, N. S., Kashtalap, V. V., Konovalov, G. A., et al. (2025) · Cardiosomatics · doi:10.17816/cs688224 · Cited by 1
Severe Hypertriglyceridemia in Pregnancy: Clinical Approach and Management Strategies
Raventós, A., Velasco, I., Ramos, A., Alonso, N., Puig‐Domingo, M., & Soldevila, B. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf253 · Cited by 3
Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes
Wahab, R. A., & Mahmood, W. A. W. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261422310 · Cited by 2
“76 Bile Acid Sequestrants (BAS) and Niacin.”
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome
Hang, S., & Hegele, R. A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2646166 · Cited by 2
“MCS patients frequently benefit from fibrates and omega-3 fatty acids, without the need in the vast majority of patients, to resort to apo C-III inhibitors to normalize TG levels [2,7,8].”
Majumdar, S. K. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.09.002 · Cited by 2
Li, Q., Qi, K., Wu, S., Shen, A., & Zhao, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117351 · Cited by 2
Severe Hypertriglyceridemia in the Hospitalized Patient
Mateo, R. C. I., & Ganda, O. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-38976-5_28 · Cited by 1
Moulin, P., & Charrière, S. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.011 · Cited by 1
Síndrome de Quilomicronemia Familiar: Algoritmo Diagnóstico
Colaco, I. B., Araújo, F., Aguiar, P., Cruz, D., Bourbon, M., Duarte, J. S., & Veríssimo, M. T. (2021) · Medicina Interna · doi:10.24950/rspmi.r.92.4.2021 · Cited by 1
Metadata
- Authors
- Chait, A., & Eckel, R. H.
- Affiliations
- University of Washington (US)
- University of Colorado Anschutz (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2019-05-07
- Volume
- 170
- Issue
- 9
- Pages
- 626-634
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2942839572
- Cited by
- 128
- References
- 94
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 16 · 2023: 12 · 2022: 25 · 2021: 12 · 2020: 27 · 2019: 4
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- chylomicronemia syndrome, hypertriglyceridemia, familial chylomicronemia syndrome, familial partial lipodystrophy, lipoprotein lipase deficiency, triglyceride-rich lipoproteins, lipoprotein clearance, eruptive xanthoma, lipemia retinalis, acute pancreatitis, treatment options
- MeSH terms
- Algorithms, Hypolipidemic Agents, Apolipoproteins, Cardiovascular Diseases, Chylomicrons, Humans, Lipoprotein Lipase, Hyperlipoproteinemia Type I, Mutation, Oligonucleotides, Pancreatitis, Risk Factors, Hypertriglyceridemia, Fatty Acids, Omega-3, Receptors, Lipoprotein, Genetic Predisposition to Disease, Angiopoietins, Lipodystrophy, Familial Partial, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.